Seoul St. Mary's Hospital is accelerating the development of a three-dimensional chondrocyte injection treatment
Aug 09, 2024
The Catholic University of Korea's Seoul St. Mary's Hospital will launch a clinical study on intraarticular injection of induced pluripotent stem cell-derived chondrospheroid MIUChon (Minimal Injectable Unit Chondrospheroid) in patients with knee osteoarthritis.
The study was approved for suitability by the Ministry of Health and Welfare's Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee and the Ministry of Food and Drug Safety at the recently held '2024 7th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee'.
Professor Joo Ji-hyun of Rheumatology at Catholic University of Korea's Seoul St. Mary's Hospital (Director of the Advanced Cell Therapy Project of the Catholic Central Medical Center), Professor Lim Ye-ri of the Institute of Induced Pluripotent Stem Cell Application at Catholic University of Korea Medical School, and Dr. Nam Yoo-jun of Ypsel Co., Ltd. will participate in this study jointly.
This study, a clinical study of allogeneic cell therapy using induced pluripotent stem cells, is significant in that it is the world's first attempt to administer 'cartilage spheroid', a circular cell aggregate in which a large number of chondrocytes are cultured in a three-dimensional form, in the form of injections rather than surgery.
Induced pluripotent stem cells (iPSC) are stem cells made by introducing genes that induce reverse differentiation into human somatic cells and have pluripotency and differentiation ability similar to embryonic stem cells.
MIUChon treatment developed in this study creates a three-dimensional chondrocyte cluster of size that can be administered through needles from these induced pluripotent stem cells and injects them into the joint cavity without surgery. It is expected to be a fundamental treatment for osteoarthritis patients by recovering damaged cartilage.
This clinical study is drawing great attention in that it is a treatment that can be administered to all osteoarthritis patients around the world without immune rejection with a single cell by utilizing the unlimited proliferation ability of induced pluripotent stem cells.
This is an innovative approach that goes beyond autologous cell therapy, which is a method of using one's own cells as a treatment only for oneself.
The research team at Seoul St. Mary's Hospital plans to start clinical research within this year to determine the safety and effectiveness of MIUChon treatments. In addition, this study presents a new paradigm for the treatment of osteoarthritis and will expand its application in various regenerative medical fields in the future.
Professor Joo Ji-hyun, Director of Research, said "MIUChon was a difficult and difficult journey that took more than three years to approve clinical research because it was an advanced regenerative treatment in a form that did not exist before.""We will do our best to develop a treatment that gives new hope to degenerative osteoarthritis patients suffering from the lack of a fundamental treatment ""
Meanwhile, the Catholic Central Medical Center Basic Medicine Project Promotion Team (Director Min Chang-ki), launched in 2023, has supported a lot of R&D costs and infrastructure such as experimental equipment for the development of advanced cell therapy, and these activities have contributed greatly to the fruit of clinical research approval for advanced regenerative cell therapy.
The study was approved for suitability by the Ministry of Health and Welfare's Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee and the Ministry of Food and Drug Safety at the recently held '2024 7th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee'.
Professor Joo Ji-hyun of Rheumatology at Catholic University of Korea's Seoul St. Mary's Hospital (Director of the Advanced Cell Therapy Project of the Catholic Central Medical Center), Professor Lim Ye-ri of the Institute of Induced Pluripotent Stem Cell Application at Catholic University of Korea Medical School, and Dr. Nam Yoo-jun of Ypsel Co., Ltd. will participate in this study jointly.
This study, a clinical study of allogeneic cell therapy using induced pluripotent stem cells, is significant in that it is the world's first attempt to administer 'cartilage spheroid', a circular cell aggregate in which a large number of chondrocytes are cultured in a three-dimensional form, in the form of injections rather than surgery.
Induced pluripotent stem cells (iPSC) are stem cells made by introducing genes that induce reverse differentiation into human somatic cells and have pluripotency and differentiation ability similar to embryonic stem cells.
MIUChon treatment developed in this study creates a three-dimensional chondrocyte cluster of size that can be administered through needles from these induced pluripotent stem cells and injects them into the joint cavity without surgery. It is expected to be a fundamental treatment for osteoarthritis patients by recovering damaged cartilage.
This clinical study is drawing great attention in that it is a treatment that can be administered to all osteoarthritis patients around the world without immune rejection with a single cell by utilizing the unlimited proliferation ability of induced pluripotent stem cells.
This is an innovative approach that goes beyond autologous cell therapy, which is a method of using one's own cells as a treatment only for oneself.
The research team at Seoul St. Mary's Hospital plans to start clinical research within this year to determine the safety and effectiveness of MIUChon treatments. In addition, this study presents a new paradigm for the treatment of osteoarthritis and will expand its application in various regenerative medical fields in the future.
Professor Joo Ji-hyun, Director of Research, said "MIUChon was a difficult and difficult journey that took more than three years to approve clinical research because it was an advanced regenerative treatment in a form that did not exist before.""We will do our best to develop a treatment that gives new hope to degenerative osteoarthritis patients suffering from the lack of a fundamental treatment ""
Meanwhile, the Catholic Central Medical Center Basic Medicine Project Promotion Team (Director Min Chang-ki), launched in 2023, has supported a lot of R&D costs and infrastructure such as experimental equipment for the development of advanced cell therapy, and these activities have contributed greatly to the fruit of clinical research approval for advanced regenerative cell therapy.
|
bellho@sportschosun.com
